Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CUTR's Cash to Debt is ranked higher than
91% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. CUTR: No Debt )
CUTR' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.76
CUTR's Equity to Asset is ranked higher than
81% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. CUTR: 0.76 )
CUTR' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.87
Current: 0.76

0.31
0.87
Interest Coverage No Debt
CUTR's Interest Coverage is ranked higher than
81% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 241.11 vs. CUTR: No Debt )
CUTR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 4.29
M-Score: -2.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -12.51
CUTR's Operating margin (%) is ranked higher than
59% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 5.49 vs. CUTR: -12.51 )
CUTR' s 10-Year Operating margin (%) Range
Min: -20.83   Max: 22.05
Current: -12.51

-20.83
22.05
Net-margin (%) -12.37
CUTR's Net-margin (%) is ranked higher than
59% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. CUTR: -12.37 )
CUTR' s 10-Year Net-margin (%) Range
Min: -32.93   Max: 18.25
Current: -12.37

-32.93
18.25
ROE (%) -11.14
CUTR's ROE (%) is ranked higher than
60% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.07 vs. CUTR: -11.14 )
CUTR' s 10-Year ROE (%) Range
Min: -16.6   Max: 56.57
Current: -11.14

-16.6
56.57
ROA (%) -8.64
CUTR's ROA (%) is ranked higher than
61% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. CUTR: -8.64 )
CUTR' s 10-Year ROA (%) Range
Min: -13.66   Max: 23.97
Current: -8.64

-13.66
23.97
ROC (Joel Greenblatt) (%) -336.60
CUTR's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 8.37 vs. CUTR: -336.60 )
CUTR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1247.08   Max: 312.88
Current: -336.6

-1247.08
312.88
Revenue Growth (%) 9.60
CUTR's Revenue Growth (%) is ranked higher than
83% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. CUTR: 9.60 )
CUTR' s 10-Year Revenue Growth (%) Range
Min: -18.1   Max: 54.9
Current: 9.6

-18.1
54.9
EBITDA Growth (%) -29.50
CUTR's EBITDA Growth (%) is ranked higher than
58% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. CUTR: -29.50 )
CUTR' s 10-Year EBITDA Growth (%) Range
Min: -29.5   Max: 89.8
Current: -29.5

-29.5
89.8
EPS Growth (%) -24.90
CUTR's EPS Growth (%) is ranked higher than
60% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. CUTR: -24.90 )
CUTR' s 10-Year EPS Growth (%) Range
Min: -29.8   Max: 159.6
Current: -24.9

-29.8
159.6
» CUTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CUTR Guru Trades in Q4 2013

Charles Brandes 31,990 sh (+104.87%)
Mario Gabelli 680,000 sh (+4.62%)
Chuck Royce Sold Out
Jim Simons 620,200 sh (-1.51%)
» More
Q1 2014

CUTR Guru Trades in Q1 2014

Jim Simons 714,000 sh (+15.12%)
Charles Brandes 32,675 sh (+2.14%)
Mario Gabelli 650,000 sh (-4.41%)
» More
Q2 2014

CUTR Guru Trades in Q2 2014

Jim Simons 793,500 sh (+11.13%)
Mario Gabelli 650,000 sh (unchged)
Charles Brandes 31,935 sh (-2.26%)
» More
Q3 2014

CUTR Guru Trades in Q3 2014

Mario Gabelli 650,000 sh (unchged)
Charles Brandes 30,805 sh (-3.54%)
Jim Simons 757,900 sh (-4.49%)
» More
» Details

Insider Trades

Latest Guru Trades with CUTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2013-12-31 Add 104.87%$8.39 - $10.56 $ 9.895%31990
Charles Brandes 2013-09-30 New Buy$8.89 - $10.18 $ 9.894%15615
Charles Brandes 2013-03-31 Sold Out 0.0015%$8.95 - $13.03 $ 9.89-13%0
Charles Brandes 2012-12-31 Reduce -61.65%$7.34 - $9.77 $ 9.8917%14543
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.76
CUTR's P/B is ranked higher than
85% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.78 vs. CUTR: 1.76 )
CUTR' s 10-Year P/B Range
Min: 0.68   Max: 5.31
Current: 1.76

0.68
5.31
P/S 1.87
CUTR's P/S is ranked higher than
79% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. CUTR: 1.87 )
CUTR' s 10-Year P/S Range
Min: 0.93   Max: 7.8
Current: 1.87

0.93
7.8
EV-to-EBIT -6.58
CUTR's EV-to-EBIT is ranked higher than
63% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 73.45 vs. CUTR: -6.58 )
CUTR' s 10-Year EV-to-EBIT Range
Min: -242.1   Max: 695.7
Current: -6.58

-242.1
695.7
Current Ratio 5.02
CUTR's Current Ratio is ranked higher than
85% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. CUTR: 5.02 )
CUTR' s 10-Year Current Ratio Range
Min: 2.5   Max: 9.09
Current: 5.02

2.5
9.09
Quick Ratio 4.47
CUTR's Quick Ratio is ranked higher than
86% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. CUTR: 4.47 )
CUTR' s 10-Year Quick Ratio Range
Min: 2.21   Max: 8.66
Current: 4.47

2.21
8.66

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.61
CUTR's Price/Net Cash is ranked higher than
98% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CUTR: 2.61 )
CUTR' s 10-Year Price/Net Cash Range
Min: 1.2   Max: 5.56
Current: 2.61

1.2
5.56
Price/Net Current Asset Value 2.14
CUTR's Price/Net Current Asset Value is ranked higher than
98% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CUTR: 2.14 )
CUTR' s 10-Year Price/Net Current Asset Value Range
Min: 1.07   Max: 5.01
Current: 2.14

1.07
5.01
Price/Tangible Book 1.82
CUTR's Price/Tangible Book is ranked higher than
90% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.57 vs. CUTR: 1.82 )
CUTR' s 10-Year Price/Tangible Book Range
Min: 0.77   Max: 20.59
Current: 1.82

0.77
20.59
Price/DCF (Projected) 4.65
CUTR's Price/DCF (Projected) is ranked higher than
83% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CUTR: 4.65 )
CUTR' s 10-Year Price/DCF (Projected) Range
Min: 0.45   Max: 4.82
Current: 4.65

0.45
4.82
Price/Median PS Value 0.91
CUTR's Price/Median PS Value is ranked higher than
85% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. CUTR: 0.91 )
CUTR' s 10-Year Price/Median PS Value Range
Min: 0.53   Max: 2.55
Current: 0.91

0.53
2.55
Earnings Yield (Greenblatt) -15.20
CUTR's Earnings Yield (Greenblatt) is ranked higher than
51% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. CUTR: -15.20 )
CUTR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 795.7
Current: -15.2

0.1
795.7
Forward Rate of Return (Yacktman) -22.16
CUTR's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 349 Companies
in the Global Medical Devices industry.

( Industry Median: 0.59 vs. CUTR: -22.16 )
CUTR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -24.2   Max: 13.8
Current: -22.16

-24.2
13.8

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Cutera Inc was established in the San Francisco Bay Area in 1998. It is a medical device company, specializing in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners. It offers easy-to-use products based on four main platforms/systems Xeo, GenesisPlus, ExcelV, and truSculpt, each of which enables physicians and other qualified practitioners to perform safe and effective aesthetic procedures for their customers. The Xeo is a multi-application platform on which a customer can purchase hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin rejuvenation by treating discoloration, improving texture, reducing pore size, and treating fine lines and laxity. GenesisPlus platform, is a dedicated laser system for performing aesthetic skin procedures and for the temporary increase of clear nail in patients with onychomycosis, or toenail fungus. ExcelV is a high-performance, vascular platform designed specifically for the core-market of Dermatologists and Plastic Surgeons. This platform provides a combination of the 532 nm green laser with Cutera's award-winning 1064 nm Nd:YAG technology, to provide a single, compact and efficient system that treats the entire range of cosmetic vascular conditions, without the need for costly consumables. truSculpt is a high-powered radio frequency platform designed for the non-invasive body contouring market. This system is designed to treat all body areas and with its electrode design is able to achieve comfortable, uniform heating of the subcutaneous fat. In the U.S. its markets and sells its products mainly through a direct sales organization. International sales are generally made through a distributor network in over 60 countries. As of December 31, 2013, the Company had 30 issued U.S. patents and 11 pending U.S. patent applications. Its registered trademarks include Cutera, Acutip 500, CoolGlide, CoolGlide Excel, Limelight, myQ, Pearl, ProWave 770, ProWave LX, Solera, Titan, Xeo and truSculpt. The Company's products competes against laser and other energy-based products offered by public companies, such as Cynosure, Elen (in Italy), Lumenis, Syneron and Zeltiq, as well as private companies, including, Alma, Sciton, and several others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, as well as other regulatory bodies.
» More Articles for CUTR

Headlines

Articles On GuruFocus.com
Chuck Royce's Top Five Second Quarter Portfolio Increases Aug 07 2013 
Gurus Buy Micro Caps – Bamboo Toilet Paper Jul 24 2013 
Guru Weekly Real Time Update Jul 05 2013 
Mario Gabelli and Jean-Marie Eveillard's Real Time Increases Jul 02 2013 
Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
Comment for Benjamin Graham Net Current Asset Value Screener Jun 03 2011 

More From Other Websites
Cutera to Present at the Canaccord Genuity 2014 Medical Technology & Diagnostics Forum and the Piper... Nov 11 2014
Cutera Receives FDA 510(k) Clearance for Tattoo Removal for enlighten(TM) Nov 06 2014
Cutera Receives FDA 510(k) Clearance for Tattoo Removal for enlighten(TM) Nov 06 2014
10-Q for Cutera, Inc. Nov 05 2014
Cutera posts 3Q loss Nov 03 2014
Cutera posts 3Q loss Nov 03 2014
Cutera Inc Earnings Call scheduled for 5:00 pm ET today Nov 03 2014
CUTERA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 03 2014
CUTERA INC Files SEC form 10-Q, Quarterly Report Nov 03 2014
Cutera Reports Third Quarter 2014 Results Nov 03 2014
Cutera Reports Third Quarter 2014 Results Nov 03 2014
Q3 2014 Cutera Inc Earnings Release - After Market Close Nov 03 2014
Cutera, Inc. to Announce Results for the Third Quarter Ended September 30, 2014 Oct 24 2014
Cutera, Inc. to Announce Results for the Third Quarter Ended September 30, 2014 Oct 24 2014
CUTERA INC Financials Aug 09 2014
Cutera Inc Earnings Call scheduled for 5:00 pm ET today Aug 04 2014
CUTERA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 04 2014
CUTERA INC Files SEC form 10-Q, Quarterly Report Aug 04 2014
CUTERA INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 31 2014
Cutera (CUTR) is in Overbought Territory: What's Next? Jul 02 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK